Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mylafent 50micrograms/hour transdermal patches
0407020A0BUACAF
|
Mylafent | Fentanyl | Central Nervous System | No data available |
|
Mylafent 75micrograms/hour transdermal patches
0407020A0BUADAG
|
Mylafent | Fentanyl | Central Nervous System | No data available |
|
Mylan Travel Sickness 15mg tablets
0406000D0BEAAAA
|
Mylan | Cinnarizine | Central Nervous System | No data available |
|
Myobloc 10,000units/2ml solution for injection vials
0409030A0BCACAC
|
Myobloc | Botulinum toxin type B | Central Nervous System | No data available |
|
Myobloc 2,500units/0.5ml solution for injection vials
0409030A0BCAAAA
|
Myobloc | Botulinum toxin type B | Central Nervous System | No data available |
|
Myobloc 5,000units/1ml solution for injection vials
0409030A0BCABAB
|
Myobloc | Botulinum toxin type B | Central Nervous System | No data available |
|
Mysoline 250mg/5ml oral suspension
0408010U0BBABBC
|
Mysoline | Primidone | Central Nervous System | No data available |
|
Mysoline 50mg tablets
0408010U0BBADAX
|
Mysoline | Primidone | Central Nervous System | No data available |
|
Nabilone 2mg capsules
0406000R0AAAJAJ
|
Nabilone | Nabilone | Central Nervous System | No data available |
|
Nabilone 500microgram capsules
0406000R0AAAHAH
|
Nabilone | Nabilone | Central Nervous System | No data available |
|
Nalbuphine 10mg/1ml solution for injection ampoules
0407020Y0AAAAAA
|
Nalbuphine hydrochloride | Nalbuphine hydrochloride | Central Nervous System | No data available |
|
Nalbuphine 20mg/2ml solution for injection ampoules
0407020Y0AAADAD
|
Nalbuphine hydrochloride | Nalbuphine hydrochloride | Central Nervous System | No data available |
|
Nalorex 50mg tablets
0410030E0BBAAAA
|
Nalorex | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 12.5mg/5ml oral suspension
0410030E0AAACAC
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 1mg capsules
0410030E0AAAQAQ
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 1mg/5ml oral solution
0410030E0AAAJAJ
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 2.5mg capsules
0410030E0AAAEAE
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 25mg/5ml oral solution
0410030E0AAAWAW
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 25mg/5ml oral suspension
0410030E0AAAGAG
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 2mg/5ml oral solution
0410030E0AAADAD
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 3.5mg capsules
0410030E0AAAPAP
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Naltrexone 3mg/5ml oral solution
0410030E0AAAHAH
|
Naltrexone hydrochloride | Naltrexone hydrochloride | Central Nervous System | No data available |
|
Natzon 0.4mg sublingual tablets
0410030A0BDACAC
|
Natzon | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Natzon 2mg sublingual tablets
0410030A0BDAAAD
|
Natzon | Buprenorphine hydrochloride | Central Nervous System | No data available |
|
Natzon 8mg sublingual tablets
0410030A0BDABAE
|
Natzon | Buprenorphine hydrochloride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.